Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel: Report of Two Cases

Caterina Longo, Stefania Borsari, Elisa Benati, Elvira Moscarella, Roberto Alfano, Giuseppe Argenziano

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction: A relatively novel application for dermoscopy and reflectance confocal microscopy (RCM) is their use in the monitoring of topical treatment response for non-melanoma skin cancer. Actinic keratosis (AK) is the early phase of a multistep biologic continuum leading to invasive squamous cell carcinoma. A number of topical therapies are now available for the treatment of AK but their disadvantages include long treatment duration and prolonged local reactions. Ingenol mebutate is a newer therapy for AK which is only applied for 2 or 3 days. Case Report: Dermoscopy and RCM findings in two patients with AK treated with ingenol mebutate confirm that it induces rapid lesion necrosis and specific neutrophil-mediated, antibody-dependent cellular cytotoxicity. Necrosis occurs via mitochondrial membrane disruption, with subsequent eradication of residual tumor cells via transient inflammation. Local skin reactions to ingenol mebutate should be considered part of the drug’s mechanism of action rather than an adverse effect. Conclusion: Ingenol mebutate is a valuable therapy for the treatment of AK. This case report adds further evidence to the usefulness of dermoscopy and RCM in the assessment and monitoring of treatment outcome.

Original languageEnglish
Pages (from-to)81-87
Number of pages7
JournalDermatology and Therapy
Volume6
Issue number1
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Dermoscopy
Actinic Keratosis
Confocal Microscopy
Gels
Therapeutics
Necrosis
Residual Neoplasm
Mitochondrial Membranes
Skin Neoplasms
3-ingenyl angelate
Squamous Cell Carcinoma
Neutrophils
Inflammation
Skin
Antibodies

Keywords

  • Actinic keratosis
  • Dermoscopy
  • Field cancerization
  • Ingenol mebutate
  • Reflectance confocal microscopy

ASJC Scopus subject areas

  • Dermatology

Cite this

Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel : Report of Two Cases. / Longo, Caterina; Borsari, Stefania; Benati, Elisa; Moscarella, Elvira; Alfano, Roberto; Argenziano, Giuseppe.

In: Dermatology and Therapy, Vol. 6, No. 1, 01.03.2016, p. 81-87.

Research output: Contribution to journalArticle

Longo, Caterina ; Borsari, Stefania ; Benati, Elisa ; Moscarella, Elvira ; Alfano, Roberto ; Argenziano, Giuseppe. / Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel : Report of Two Cases. In: Dermatology and Therapy. 2016 ; Vol. 6, No. 1. pp. 81-87.
@article{4372c1e627a44f15884985821b19e186,
title = "Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel: Report of Two Cases",
abstract = "Introduction: A relatively novel application for dermoscopy and reflectance confocal microscopy (RCM) is their use in the monitoring of topical treatment response for non-melanoma skin cancer. Actinic keratosis (AK) is the early phase of a multistep biologic continuum leading to invasive squamous cell carcinoma. A number of topical therapies are now available for the treatment of AK but their disadvantages include long treatment duration and prolonged local reactions. Ingenol mebutate is a newer therapy for AK which is only applied for 2 or 3 days. Case Report: Dermoscopy and RCM findings in two patients with AK treated with ingenol mebutate confirm that it induces rapid lesion necrosis and specific neutrophil-mediated, antibody-dependent cellular cytotoxicity. Necrosis occurs via mitochondrial membrane disruption, with subsequent eradication of residual tumor cells via transient inflammation. Local skin reactions to ingenol mebutate should be considered part of the drug’s mechanism of action rather than an adverse effect. Conclusion: Ingenol mebutate is a valuable therapy for the treatment of AK. This case report adds further evidence to the usefulness of dermoscopy and RCM in the assessment and monitoring of treatment outcome.",
keywords = "Actinic keratosis, Dermoscopy, Field cancerization, Ingenol mebutate, Reflectance confocal microscopy",
author = "Caterina Longo and Stefania Borsari and Elisa Benati and Elvira Moscarella and Roberto Alfano and Giuseppe Argenziano",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s13555-016-0094-9",
language = "English",
volume = "6",
pages = "81--87",
journal = "Dermatology and Therapy",
issn = "2190-9172",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel

T2 - Report of Two Cases

AU - Longo, Caterina

AU - Borsari, Stefania

AU - Benati, Elisa

AU - Moscarella, Elvira

AU - Alfano, Roberto

AU - Argenziano, Giuseppe

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Introduction: A relatively novel application for dermoscopy and reflectance confocal microscopy (RCM) is their use in the monitoring of topical treatment response for non-melanoma skin cancer. Actinic keratosis (AK) is the early phase of a multistep biologic continuum leading to invasive squamous cell carcinoma. A number of topical therapies are now available for the treatment of AK but their disadvantages include long treatment duration and prolonged local reactions. Ingenol mebutate is a newer therapy for AK which is only applied for 2 or 3 days. Case Report: Dermoscopy and RCM findings in two patients with AK treated with ingenol mebutate confirm that it induces rapid lesion necrosis and specific neutrophil-mediated, antibody-dependent cellular cytotoxicity. Necrosis occurs via mitochondrial membrane disruption, with subsequent eradication of residual tumor cells via transient inflammation. Local skin reactions to ingenol mebutate should be considered part of the drug’s mechanism of action rather than an adverse effect. Conclusion: Ingenol mebutate is a valuable therapy for the treatment of AK. This case report adds further evidence to the usefulness of dermoscopy and RCM in the assessment and monitoring of treatment outcome.

AB - Introduction: A relatively novel application for dermoscopy and reflectance confocal microscopy (RCM) is their use in the monitoring of topical treatment response for non-melanoma skin cancer. Actinic keratosis (AK) is the early phase of a multistep biologic continuum leading to invasive squamous cell carcinoma. A number of topical therapies are now available for the treatment of AK but their disadvantages include long treatment duration and prolonged local reactions. Ingenol mebutate is a newer therapy for AK which is only applied for 2 or 3 days. Case Report: Dermoscopy and RCM findings in two patients with AK treated with ingenol mebutate confirm that it induces rapid lesion necrosis and specific neutrophil-mediated, antibody-dependent cellular cytotoxicity. Necrosis occurs via mitochondrial membrane disruption, with subsequent eradication of residual tumor cells via transient inflammation. Local skin reactions to ingenol mebutate should be considered part of the drug’s mechanism of action rather than an adverse effect. Conclusion: Ingenol mebutate is a valuable therapy for the treatment of AK. This case report adds further evidence to the usefulness of dermoscopy and RCM in the assessment and monitoring of treatment outcome.

KW - Actinic keratosis

KW - Dermoscopy

KW - Field cancerization

KW - Ingenol mebutate

KW - Reflectance confocal microscopy

UR - http://www.scopus.com/inward/record.url?scp=84961825258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961825258&partnerID=8YFLogxK

U2 - 10.1007/s13555-016-0094-9

DO - 10.1007/s13555-016-0094-9

M3 - Article

AN - SCOPUS:84961825258

VL - 6

SP - 81

EP - 87

JO - Dermatology and Therapy

JF - Dermatology and Therapy

SN - 2190-9172

IS - 1

ER -